Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491434 | 0.89 | SLC6A4 (0.40) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL29155288 | 0.79 | SLC6A3 (0.67) | SLC6A3SLC6A4DPP4SLC6A2 | |
| SCHEMBL29155232 | 0.79 | SLC6A3 (0.62) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL19950062 | 0.74 | SMN1; SMN2 (0.41) | — | |
| Hydrochloric Acid SCHEMBL29428955 | 0.73 | SLC6A3 (0.47) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL3223371 | 0.72 | MAOA (0.59) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL4925293 | 0.72 | MAOA (0.59) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL23231420 | 0.71 | S1PR2 (0.34) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL1672596 | 0.70 | SLC6A3 (0.81) | SLC6A3SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL987779 | 0.70 | MAOA (0.61) | SLC6A3SLC6A4MAOAMAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-109923114-B | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3510032-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | Incyte Corporation (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | SLC6A3 4076/4885SLC6A4 3975/4885MAOA 2022/4885 |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | SLC6A3 4076/4885SLC6A4 3975/4885MAOA 2022/4885 |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SLC6A3 4076/4885SLC6A4 3975/4885MAOA 2022/4885 |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SLC6A3 4076/4885SLC6A4 3975/4885MAOA 2022/4885 |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | SLC6A3 4076/4885SLC6A4 3975/4885MAOA 2022/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SLC6A3 4076/4885SLC6A4 3975/4885MAOA 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.